Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QIAGEN (QGENF) - Star of Germany's Biotechs -- Ignore unavailable to you. Want to Upgrade?

To: Charlie Schultz who wrote (49)	3/19/1998 11:11:00 AM
From: Vector1	Read Replies (2) \| Respond to of 122

<<On a biotech company I do not think a high p/e is cause for alarm, especially for a company of Qiagens stature.>> Let me first say I have a short position on this stock. However, multiples of earning are how companies like QGENF should be valued. QGENF is not a drug discovery company but a biological tools company. In fact it is a solid company that will probably grow earnings at 25-35% for the next two or three years. The company's current valuation of in excess of 1.2 billion and 150 trailing earnings is simply not sustainable and the stock willeventually fall. Fair value for this company is $40 per share. I can not imagine what folks paying over $70 per share are thinking. V1